Related Experiment Video
Updated: Jul 3, 2026

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
What should convince a clinician of disease modification in Alzheimer's disease clinical trials?
Jemma Hazan1,2, Kathy Y Liu1,2, Robert Howard1,2
1Division of Psychiatry, University College London, London, UK.
Abstract:
The recent publication of extension data from post-regulatory trials of amyloid-lowering antibody therapies, such as donanemab and lecanemab, requires clinicians to critically appraise trial designs and analyses in order to evaluate claims made by authors and sponsors of disease modification. This Perspective outlines the challenges with assessing claims of disease course modification, provides a framework for their evaluation, reviews the different trial designs and analytical approaches used to test or support them, and proposes a practical appraisal checklist for evaluating studies.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Clinical Trials
There are four phases in a clinical trial. A phase one...
Alzheimer Disease ll: Pathophysiology
Clinical Trials: Overview